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1169-050 Lisbon, PortugalAbstract Phototherapy is a valuable therapeutic tool in Dermatology, but there may be drawbacks.
Acute and long-term adverse effects, of variable severity, include skin erythema, xerosis, pruritus, blis-
tering, altered pigmentation, photoaging, and photocarcinogenesis. Despite concerns over the carcino-
genic potential of ultraviolet radiation, most studies have not found an increased risk of non-melanoma
or melanoma skin cancer in patients treated with ultraviolet B (broadband and narrowband) and ultra-
violet A1 phototherapy. These are therefore considered reasonably safe treatment modalities concern-
ing the development of skin neoplasms, although caution and further investigation are warranted.
Photoprotective measures, such as avoidance of concurrent sunlight exposure and covering skin areas
not afﬂicted with disease, or more modern strategies, including phytochemical antioxidants and exog-
enous DNA repair enzymes, can minimize the hazards of phototherapy. Patients submitted to photo-
therapeutic regimens should undergo complete, careful dermatologic examination regularly and
lifelong.
© 2016 Elsevier Inc. All rights reserved.Introduction
The development of artiﬁcial light sources has led to great
advances in phototherapy during the last decades, allowing
its common use for multiple conditions in Dermatology.1
The beneﬁcial effects in many inﬂammatory dermatoses and
lymphoproliferative skin diseases are thought to result largely
from the ability of ultraviolet radiation (UVR) to induce im-
munosuppression and alter cell proliferation; however,⁎ Corresponding author: Institutional address: Department of Dermatology
and Venereology, Centro Hospitalar de Lisboa Central, Alameda de Santo
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trum of possible adverse effects of variable severity, the most
worrisome being the potential of UVR to induce or stimulate
skin carcinogenesis.
This concern is justiﬁed by the well-established epidemio-
logic link between solar UVR exposure and an increased risk
of skin cancer, as well as by the evidence that UVR, by impair-
ing immunologic mechanisms of tumor surveillance while dis-
turbing DNA stability, can trigger skin carcinogenesis.
However, the magnitude of the photocarcinogenic risk of pho-
totherapy is not yet deﬁnitely established. We review the ad-
verse effects of phototherapy, and particularly the state-of-
the-art evidence about the development of skin malignant neo-
plasms in patients treated with this modality, and preventive
strategies to minimize such potential risk.spitalar Lisboa Central September 23, 2016.
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The use of artiﬁcial UVR for therapeutic purposes started
with the combination of topical coal tar and subsequent ultra-
violet (UV) irradiation by William Goeckerman (1884-1954)
in 1925. The use of broadband ultraviolet B (BBUVB) radia-
tion (280-315 nm) alone began in the 1970s; ﬂuorescent lamps
of BBUVBdevices emit a wide range of wavelengths (approx-
imately two thirds in the UVB range, the rest primarily in the
ultraviolet A [UVA] range). Psoralen-UVA photochemother-
apy (PUVA), combining oral or topical psoralens and subse-
quent UVA exposure, was initiated in the 1970s. Later, the
potential of selectively using a subset of the UVB spectrum
was explored. Fluorescent bulbs, emitting narrowband UVB
(NBUVB) radiation at 311 - 313 nm, were a major advance,
giving rise to a more effective and less harmful treatment.
UVA1 (340-400 nm) phototherapy, a more recent and safer
alternative to PUVA, uses longer wavelength UVR, which
penetrates deeper and targets cells residing in or inﬁltrating
the dermis.2
Phototherapy has revolutionized Dermatology and is of un-
questionable value. In fact, because UVR suppresses the im-
mune system in a more speciﬁc fashion, phototherapy can
have fewer side effects than conventional, broader immuno-
suppressive drugs.3The dark side of the light: adverse effects of
phototherapy
The UVR used in phototherapy is nevertheless a double-
edged sword, whose harmful potential has to be considered.
Varying in severity, there are both short-term and long-term,
wavelength-dependent adverse effects attributed to photother-
apy (Table 1).
Short-term side effects of UVB phototherapy on skin in-
clude sunburnlike erythema (NBUVB being approximately
5-10 times less erythemogenic than BBUVB4), xerosis accom-
panied by pruritus, occasional blistering, and an increasedTable 1 Short- and long-term adverse effects of phototherapy
Short-term adverse effects Long-term adverse effects
Skin Skin
Erythema Photoaging
Xerosis Photocarcinogenesis
Pruritus
Blistering
Altered pigmentation
(mostly hyperpigmentation)
Herpes simplex infections
(recurrence)
Eye Eye
Photoconjunctivitis Cataractogenesis
Photokeratitis
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adverse effects of UVA1 are less severe than those of UVB,1
with studies reporting a low frequency of side effects in
UVA1-treated patients2; severe acute adverse effects of
UVA1 phototherapy have not been reported, whereas com-
mon mild acute adverse effects include altered pigmentation
(mostly hyperpigmentation), xerosis, and pruritus; although
UVA1 is not highly erythemogenic, phototoxicity may occur,
especially among individuals with lower skin phototypes.2,6
PUVA is highly associated with these and other adverse ef-
fects, including enhanced systemic toxicity.
Long-term exposure to UVB, UVA1, or PUVA causes pro-
found changes in the skin, including photoaging, cumulative
actinic damage, and possibly photocarcinogenesis.1,5 Skin car-
cinogenesis is the most feared potential adverse effect of pho-
totherapy, especially in prolonged, repeated phototherapeutic
regimens, due to the UVR capacity to disturb the DNA struc-
ture and impair tumor immunosurveillance mechanisms.
Phototherapy can also be ophthalmologically hazardous,
potentially causing photoconjunctivitis and photokeratitis.5
Unprotected eye exposure to UVB and deeper-penetrating
UVA can even induce cataracts.7
Phototherapy and photocarcinogenesis: what is the
evidence?
Although there is great concern among dermatologists and
patients about the potential of UV phototherapy to induce or
stimulate skin carcinogenesis, the actual magnitude of this risk
has yet to be fully delineated. First, the design of most studies
has been generally suboptimal: many are retrospective analy-
ses with low sample sizes and short follow-up times. Second,
there are several confounding factors to be taken into consider-
ation: for instance, studies on phototherapy-associated carci-
nogenesis generally fail to precisely quantify solar exposure,
which is particularly relevant considering that patients with
phototherapy-responsive dermatoses might seek more natural
sunlight; moreover, patients submitted to phototherapy have
often undergone many other topical and, more importantly,
systemic therapies, some of which have carcinogenic poten-
tial. In addition, the vast majority of data available on this topic
have been obtained from psoriatic patients, because they repre-
sent the largest group receiving phototherapy. Finally, regular
dermatologic follow-up of treated patients accounts for some
diagnostic bias, because they are more likely to have skin can-
cers detected, excised, classiﬁed, and registered.
We review here the state-of-the-art evidence about the de-
velopment of skin malignant neoplasms in patients treated
with different phototherapy modalities.
PUVA therapy
Although a thorough discussion about PUVA is beyond the
scope of this paper, it is important to mention that this form of
photochemotherapy has been better studied than the remaining
phototherapy modalities and proven to have a well-established
role in human photocarcinogenesis. PUVA is associated withitalar Lisboa Central September 23, 2016.
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(NMSC) (particularly squamous cell carcinoma [SCC] and,
to a lesser extent, basal cell carcinoma [BCC], as well as Mer-
kel cell carcinoma) and melanoma –, also in non-exposed skin
areas, with a clear dose–effect relationship.8–18 About 15
years after the ﬁrst treatment with PUVA, the risk ofmalignant
melanoma increases, especially among patients receiving 250
or more treatments.12 This effect is apparent even with low-
dose exposures and may persist for many years after cessation
of treatment.8–18
UVB phototherapy
The ﬁrst published study on the rate of skin cancer in pa-
tients treated with UVB (Goeckerman therapy) appeared in
1980, where 305 patients with atopic dermatitis were followed
up for 25 years, during which 11 were diagnosed with
NMSC.19 In 1981, a study on skin cancer incidence in psoriat-
ic patients treated with tar and UVB phototherapy showed no
increased risk, as only 19 patients out of 260 developed
NMSC in up to 25 years.20 In a retrospective analysis of a co-
hort of psoriatic patients, there was no additional increased risk
for skin cancer in those treated with tar and UVB.21 Another
study, in which 85 psoriatic patients were extensively treated
with UVB for up to 25 years, found no signiﬁcant difference
of prevalence of premalignant/malignant skin lesions in those
patients (5.9%) from the control group (10.1%).22 In a study of
2247 psoriatic patients for up to 15 years, there was an unex-
pected non-signiﬁcant lower incidence of NMSC in those
treated with UVB (1.2%), compared with control non-treated
patients (1.8%).23 A cohort study including 5687 psoriatic pa-
tients revealed a non-signiﬁcant relative risk of 1.6 for the de-
velopment of SCC with UVB treatment.24 An important
confounder of such studies assessing the photocarcinogenic
risk of UVB phototherapy is that most patients received pri-
marily other treatment modalities.
The American “PUVA Follow-up Study”,9–14,17,25–27 a
16-center prospective, long-term safety trial of PUVA therapy,
analyzed the skin cancer incidence upon UVB phototherapy
among 1380 psoriatic patients. In 1980, the ﬁrst analysis of
this cohort revealed an odds ratio of 4.7 for cumulative inci-
dence of NMSC in patients with high UVB exposure25; how-
ever, in an updated corrected analysis the relationship between
exposure to UVB phototherapy and NMSC risk was no longer
apparent.11 Later, high UVB exposure (≥300 treatments) was
found to be associatedwith a modest but signiﬁcant increase in
SCC and BCC risk, with such skin tumors developing on an-
atomic sites typically exposed during UVB phototherapy (tor-
so, buttocks, and legs) but not on chronically sun-exposed sites
such as the head and neck27; this was most apparent among in-
dividuals with previous low PUVA exposure (b100 treat-
ments).27 Nevertheless, no difference in the risk of NMSC
was documented between patients moderately exposed to
UVB (100-299 treatments) and those exposed to only 1-99
treatments.27 Interestingly, an increase (relative risk of 4.6)
was found in genital tumors in men from the PUVA cohort
treated with high doses of UVB phototherapy.10 However, itDownloaded from ClinicalKey.com at Centro Ho
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share the confounding factor of previous exposure to PUVA,
which is ﬁrmly associated with an increased risk of skin
cancer.
In a study of 496 psoriatic patients also previously treated
with PUVA, 111 were treated with UVB as well; 11 cases of
skin cancer occurred among the 385 patients not exposed to
UVB, whereas only 2 were found in the UVB-treated, result-
ing in a non-signiﬁcant relative risk (0.36) of NMSC after
UVB therapy.28
In 2014, a cross-sectional study found 8 cases (4.9%) of
histopathologically veriﬁed NMSC among 162 psoriatic pa-
tients treated with UVB, some of whom had previously re-
ceived PUVA, among other treatments; the risk of skin
cancer correlated with the number of UVB treatments, but
the overall risk of malignancy in the UVB-treated patients
was not greater than in the general control population.29
Among several reports, only three cases of melanoma were
identiﬁed among approximately 1000 UVB-treated pa-
tients.21,30 No study provided a relative risk for melanoma.31
Although UVB itself is a known carcinogen, worldwide
data accumulated over recent decades suggest that the risk
of non-genital skin cancer (melanoma or non-melanoma)
is not signiﬁcantly increased by UVB phototherapy. Even
though high cumulative UVB exposure might confer a
modest increase in NMSC risk, its carcinogenic potential
is still signiﬁcantly (about seven times) lower than that at-
tributed to PUVA27; moreover, given the relatively small un-
derlying tumor incidence on the anatomic sites preferentially
affected by phototherapy, even an increased relative risk of
NMSC in these sites does not translate into a substantially
higher absolute incidence of tumors.27 UVB phototherapy ap-
pears to have a reasonably positive safety proﬁle, remaining a
relatively low-risk treatment option for many dermatologic
conditions.
NBUVB phototherapy
NBUVB is clinically more effective than BBUVB, requir-
ing lower dosages to achieve therapeutic response, and is con-
sidered less carcinogenic.1 Because it has only recently been
introduced as a therapeutic tool, the long-term carcinogenic
risk of NBUVB is, however, not yet ﬁrmly established.18,31
There are conﬂicting data from murine studies,32–36 and only
a few studies in humans have considered its relative
carcinogenicity.
Prospective studies in patients treated with NBUVB are
lacking.18 A systematic review18 from 2012 identiﬁed only
four retrospective studies4,37–39 focusing on the potential car-
cinogenic risk of NBUVB used for psoriasis; none of them
suggested an alarming increase in the risk of NMSC or mela-
noma. In a 2004 report about the incidence of skin tumors in
195 psoriatic patients receiving BBUVB or NBUVB, only 1
patient treated with NBUVB developed skin cancer (in situ
melanoma), and this happened within the ﬁrst year of photo-
therapy, most likely ruling out treatment-related photocarcino-
genesis.4 In 2005, another group saw no increased incidencespitalar Lisboa Central September 23, 2016.
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NBUVB, with 4 years of median follow-up and a median cu-
mulative number of treatments of 23 (1-199)37; however, a
small but signiﬁcant increase of BCC was detected with
NBUVB use (10 patients developed BCCs, whereas 4-7 were
expected in the control population).37 A 2006 report found that
the skin cancer rate recorded among 484 patients treated with
NBUVB for a variety of skin disorders (mostly psoriasis) was
as expected in the general population.38 Another group, aiming
to deﬁne the long-term carcinogenic risk of NBUVB treatment
in humans, studied 3867 patients for up to 22 years (24,753
person-years), with a median cumulative number of 29 treat-
ments (352 patients received≥100 treatments)39; their results,
published in 2008, indicated no signiﬁcant association be-
tween NBUVB treatment and BCC, SCC, or melanoma, with
a modest greater incidence of BCCs among patients also treat-
ed with PUVA.39
If the carcinogenic risk of NBUVB were as great as that of
other treatment modalities, such as PUVA, then an increased
cancer incidence would have been expected to have been de-
tected by now.39 NBUVB is therefore considered a well-
tolerated form of phototherapy so far, possibly even less carci-
nogenic than BBUVB.1 Nevertheless, these reassuring results
should be cautiously interpreted, because the slow evolution of
skin cancers may result in a delayed incidence peak yet to be
reached in the treated patients.39 Also, relatively few patients
have been exposed to high-NBUVB in the published stud-
ies.39 Ongoing risk assessment is essential, and longer monitor-
ing and treatment periods in larger, controlled prospective
studies are needed for accurate assessment of the carcinogenic
risk of NBUVB phototherapy.18,31Table 2 Preventive strategies against the potential adverse ef-
fects of phototherapy
General measures
Limiting UVR (cumulative) dose
Quantitative UV dosimeters
Avoidance of concurrent sunlight exposure
Regular complete dermatologic examination
UVR blockade
Facial protection (eg, SPF50+ sunscreen)
UV-blocking goggles or contact lenses
Genital shielding
Countering UV damage
Antioxidant agents (oral/topical)
Vitamin A, retinoids
COX-2 inhibitors, NSAIDs
PAF and 5-HT2A receptor antagonists
Xenogenic DNA repair enzymes (T4N5, photolyase, OGG1)
5-HT, serotonin; COX-2, cyclooxygenase 2; NSAIDs, nonsteroidal anti-
inﬂammatory drugs; OGG1, 8-oxoguanine DNA glycosylase 1; PAF,
platelet-activating factor; SPF, sun protection factor; T4N5, T4 endonu-
clease V; UV, ultraviolet; UVR, ultraviolet radiation.UVA1 phototherapy
UVA1 phototherapy has been found to be relatively free of
side effects.2 Since the widespread use of this modality began,
no serious associated negative side effects in humans have
been reported.1 Nevertheless, concerns about the potential
photocarcinogenic risk of UVA1 phototherapy (especially
for the development of melanoma) still persist because thor-
ough investigation on this topic has not been pursued.
There has been a single case report of melanoma develop-
ing in a patient with mastocytosis who received intense
UVA1 treatment40; however, this patient had previously re-
ceived PUVA bath therapy, so a deﬁnite link between melano-
ma and UVA1 phototherapy could not be established.40 Two
cases of Merkel cell carcinoma have also been reported in im-
munocompromised patients treated with high-dose UVA1.41
The results of a European prospective longitudinal study,
intending to monitor patients treated with UVA1 phototherapy
for the development of skin cancer, are awaited.1
Considering this, UVA1 phototherapy is an option for sev-
eral skin conditions, but cautious treatment regimens are rec-
ommended1 because its true carcinogenic risk has not been
determined. As for NBUVB, continuous risk assessment and
further investigation are required.Downloaded from ClinicalKey.com at Centro Hosp
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The acute and long-term side effects of phototherapy can be
prevented, or at least minimized, by judiciously limiting and
recording the UVR dose and the number of treatment sessions,
adjusted accordingly to skin phototype (Table 2). However,
because most dermatologic conditions requiring phototherapy
are chronic, repeated sessions are generally necessary, leading
to higher cumulative levels of UVR; consequently, the lifetime
probability of adverse events, including mutagenic effects, can
be higher. Findings from clinical research permit cautious op-
timism when pondering the skin cancer risk of phototherapy.
In fact, unlike for PUVA, there is currently no clear recom-
mendation on the number of sessions, after which photothera-
py with UVB (BBUVB or NBUVB) and UVA1 must be
discontinued to hedge their potential photocarcinogenic risk.
Quantitative UV dosimeters for phototherapy (Table 2) would
allow determination of the energy absorbed by the skin targets.
Dermatologists could thus maximize the biologic therapeutic
effects of UVR, while minimizing the hazardous conse-
quences of overexposure; however, this is an underdeveloped
area.42
Safety measures are recommended for photoprotection of
patients undergoing phototherapy (Table 2)5,6:
1. The face, if not involved, should be protected either by
sunscreen with sun protection factor (SPF) of 50+ or a
cloth barrier.
2. The eyes should be protected by wearing UV-blocking
goggles; patients with photoresponsive dermatoses in-
volving the eyelids may use UV-blocking contact lenses
instead; eyelids themselves block the majority ofitalar Lisboa Central September 23, 2016.
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because eyelid closure may be incomplete, or patients
may inadvertently open their eyes during phothoterapy.43
3. If not afﬂicted, the genitalia should be shielded (by un-
derwear, for instance).
4. Concurrent natural sun exposure should be avoided.
Importantly, patients should undergo a thorough dermato-
logic examination before starting phototherapy and be moni-
tored regularly and lifelong for the development of
signiﬁcant actinic damage, premalignant lesions, and skin ma-
lignancies (Table 2). Follow-up care should be continued even
after the eventual treatment discontinuation, because an in-
creased cancer risk persisting afterward cannot be securely
ruled out at this point. Educating patients to perform skin
self-examination is also of great value.
UV-induced oxidative stress is a major contributor to
photocarcinogenesis, conditioning skin cell mutagenesis,
tissue remodeling, inﬂammation, and immunosuppression.
As a result, photoprotective strategies using oral, or to a
lesser extent topical, antioxidant agents, namely phyto-
chemical derivatives, have gained increased attention for
their potential anti-neoplastic properties (Table 2).44–47
Such botanic antioxidants include polyphenols (ﬂavonoids
and non-ﬂavonoids), non-phenolic derivatives, and whole
plant extracts, which are present in various vegetables, fruits,
beans, cereals, and beverages, such as tea, cocoa, and wine.
These can also be found as concentrated dietary supplements
and skin care products.44–47
Vitamin A and its derivatives are largely beneﬁcial in
preventing skin cancer (Table 2) because they promote differ-
entiation, growth arrest, and apoptosis of epidermal keratino-
cytes.31,45,48 Retinoids have actually been found effective in
preventing NMSC in high-risk patients, namely those submit-
ted to large doses of PUVA.49 Associating these agents with
phototherapy treatment regimens may have potential anti-can-
cer beneﬁts in the long term. Topical retinoids should, however,
be used cautiously because they may cause photosensitivity
which is why these agents are commonly not used
simultaneously.
The synthesis of cyclooxygenase 2 (COX-2), not constitu-
tively expressed in normal epidermis, is markedly increased
after UVR exposure.48 This enzyme is required for the forma-
tion of prostaglandin E2, which has been implicated in UV-
induced tumor promotion and progression.48 Considering this,
COX-2 inhibitors (Table 2), such as celecoxib, have been used
in animal models to prevent UV-induced skin cancers with
success.50–52 Epidemiologic evidence suggests that patients
taking nonsteroidal anti-inﬂammatory drugs (NSAIDs) on a
regular basis have lower incidence of SCCs.53
The platelet-activating factor (PAF) and cis-urocanic acid
(binding to the receptor 5-HT2A) are also mediators of photo-
immunosuppression and photocarcinogenesis. The preventive
potential of PAF and 5-HT2A receptor antagonists is being ex-
plored (Table 2),54,55 with mice experiments indicating their
ability to reverse photocarcinogenesis by accelerating UV-Downloaded from ClinicalKey.com at Centro Ho
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(NER) complex.54
Considering the key role of DNA repair systems in prevent-
ing photocarcinogenesis, three xenogenic DNA repair en-
zymes are therapeutic candidates for reversing UV-induced
damage in human skin when applied topically in liposomal
form (Table 2)56:
1. T4 endonuclease V (T4N5) is a bacterial enzyme that
prevents mutations in UV-irradiated keratinocytes by re-
moving cyclobutane pyrimidine dimers (CPDs); it has
been found to reduce the incidence of actinic keratoses
and BCCs in patients with NER defects.57
2. Photolyase, derived from a photosynthetic plant, has been
proven effective in reverting DNA photoproducts (CPDs
and 6-4 photoproducts) after UVB irradiation when given
in exogenous preparations.58
3. Exogenous oxoguanine DNA glycosylase-1 (OGG1),
the enzyme recognizing and initiating the repair of
UV-induced DNA oxidative damage (8-oxoG), has pro-
duced reductions in skin tumor size and malignant trans-
formation rates in UV-irradiated mice.59
These promising results suggest that the use of skin care
products containing such enzymes may be of interest in the re-
versal of photodamage and for skin cancer prevention in pa-
tients treated with phototherapy.Conclusions and perspectives
The use of UV light in Dermatology is a double-edged
sword, having both therapeutic and harmful effects, the most
feared being photocarcinogenesis. Although both UVB and
UVA are established skin carcinogens and are associated with
the development of skin neoplasms in humans, current photo-
therapy protocols have not been found to be signiﬁcantly asso-
ciated with an increased risk of skin cancer. Unlike for PUVA,
the best available evidence regarding the carcinogenic risk of
phototherapy is reassuring, especially when considering the
increasingly used selective spectra (NBUVB and UVA1).
Phototherapy is currently cautiously assumed to be a reason-
ably safe treatment option, provided that photoprotective mea-
sures and regular, lifelong clinical vigilance are guaranteed.
Ongoing risk assessment is required, and the need for fur-
ther investigation cannot be overemphasized. Larger, con-
trolled prospective studies, with longer follow-up and
treatment periods, would not only enlighten us about the true
carcinogenic risk of phototherapy but also improve educated
risk–beneﬁt clinical decision making.Acknowledgment
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